Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — BofA Securities Tech Solutions for Drug Discovery Conference 2021
18 slides from Abcellera Biologics's conference presentation, Sep 20, 2021
Slide 1: Technology Solutions for Drug Discovery
BANK OF AMERICA TECHNOLOGY SOLUTIONS FOR DRUG DISCOVERY A B C E L L E R A Carl Hansen, CEO © SEPTEMBER 20, 2021 C O P Y R I G H T
Slide 2: Disclaimer
DISCLAIMER B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y This presentation contains forward-looking statements, including statements These statements involve risks, uncertainties and other factors that may cause made pursuant to the safe harbor provisions of the P
Slide 3: AbCellera: Drug discovery faster, more efficient and more cost effective
3 C O P YR I G H T © A B C E L L E R A B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y ABCELLERA DRUG DISCOVERY FASTER, MORE EFFICIENT & MORE COST EFFECTIVE.
Slide 4: Limited tech and limited access limits impact
B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y THE PROBLEM Drug development fails too often, takes too long and costs too much. LIMITED TECH & LIMITED ACCESS LIMITS IMPACT ~$3 ~9.4 to >90% + billion 12 years failure rate The average cost of The time it takes an C O
Slide 5: Breaking bottlenecks in a $140B+ antibody therapeutics market
THE MARKET New technologies and a new business B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y model are needed to lead antibody discovery and capture the antibody-based therapeutic market. BREAKING BOTTLENECKS IN A $140B+ ANTIBODY THERAPEUTICS MARKET. C O P YR I G
Slide 6: Unlock the natural antibody database to find new treatments
THE OPPORTUNITY UNLOCK THE NATURAL ANTIBODY B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y DATABASE TO FIND NEW TREATMENTS. But it’s been challenging to access the database. Billions of unique Each is made by Finding the best antibodies inside a single cell. antibo
Slide 7: Revitalize drug discovery with modern technologies
REVITALIZE DRUG DISCOVERY B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y WITH MODERN TECHNOLOGIES We believe our technology advantage comes from combining three things: 1 2 3 Proprietary technologies Custom software to Artificial intelligence and that can generate
Slide 8: B AN K O F AM E R I C A T E C
8 C O P YR I G H T © A B C E L L E R A B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y
Slide 9: Forward integration to accelerate drug development
FORWARD INTEGRATION TO B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y ACCELERATE DRUG DEVELOPMENT ABCELLERA PARTNER COMMERCIAL DEVELOPMENT DEVELOPMENT SALE Phase 1 Phase 2 Phase 3 & Approval Antibody Discovery Preclinical C O P YR I G H T © A B C E L L E R A Expans
Slide 10: Centralization to drive a flywheel of continuous learning and data science
C O P YR I G H T © A B C E L L E R A 10 B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y CONTINUOUS LEARNING & DATA SCIENCE. CENTRALIZATION TO DRIVE A FLYWHEEL OF
Slide 11: Help the industry and share in the success
HELP THE INDUSTRY & B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y SHARE IN THE SUCCESS. PARTNER BIOTECH, PHARMA Pre-clinical Phase 1 Phase 2 Phase 3 Approval Commercial Sale target mAb ABCELLERA Building a diversified portfolio of milestones & royalties (primary v
Slide 12: Create and capture value with deeper positions
B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y CREATE & Equity / Equity-like CAPTURE VALUE WITH DEEPER Royalties & POSITIONS Milestones Diverse deal structures provide the opportunity to deepen our position in successful molecules: C O P YR I G H T © A B C E L L E
Slide 13: Partnering with drug developers of all sizes
PARTNERING WITH DRUG DEVELOPERS OF ALL SIZES B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y C O P YR I G H T © A B C E L L E R A + UNDISCLOSED PARTNERS including large cap pharmaceutical and biotechnology companies of all 13 sizes
Slide 14: Diverse portfolio that already covers most therapeutic areas
DIVERSE PORTFOLIO THAT B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y ALREADY COVERS MOST THERAPEUTIC AREAS 138 + PR O G R AM S U N D ER C O N T R AC T therapeutic area KNOWN therapeutic area TBD oncology / neuro-degeneration / pain allergic inflammation / ophthalm
Slide 15: Unlock new targets
UNLOCK NEW TARGETS B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y Our partners look to us to unlock new targets across a range of target types. For targets that have been selected by our partners, a third include challenging, high-value targets: 28% 72% DIFFICULT t
Slide 16: Empower new modalities for next-gen therapies
B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y EMPOWER NEW MODALITIES bispecific FOR NEXT-GEN IgGs, IgMs, IgAs antibodies THERAPIES single chain radioisotope antibodies conjugates Our platform is an operating system designed to support many next-gen modalities, inc
Slide 17: Antibodies for COVID-19
2 ANTIBODIES bamlanivimab + etesevimab B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y FOR COVID-19 Bamlanivimab alone and together with etesevimab has been used to treat more than 535,000 patients, potentially preventing 20,000+ hospitalizations and 10,000 deaths.
Slide 18: Thank you
C O P YR I G H T © A B C E L L E R A 18 B AN K O F AM E R I C A T E C H S O L U T I O N S F O R D R U G D I S C O V E R Y YOU THANK
AbCellera Biologics — BofA Securities Tech Solutions for Drug Discovery Conference 2021 on 6ix